Guideways BV

Based in the Netherlands, Guideways BV provides AI-driven solutions designed to streamline regulatory approval processes in the medtech industry, enhancing efficiency for manufacturers and regulators alike. Guideways BV specializes in developing technology to facilitate regulatory approval for medical devices. Founded in 2024 in Utrecht, Netherlands, In November 2025, Guideways BV raised EUR1 million in pre-seed funding led by new investors Healthy. Capital , with participation from another new investor Rising Star Venture.

The firm's operations have remained consistent without noted pivots, and there are no mentions of subsidiaries or parent companies. The founder's history is not detailed in available information. Guideways. ai specializes in providing innovative AI-driven solutions aimed at streamlining regulatory approval processes within the medtech industry.

Their core offerings include generative AI agents that automate critical tasks such as regulatory approval strategy, submission preparation, post-market surveillance, quality management system (QMS) design, and reimbursement assessments. This technology is designed to enhance efficiency by reducing manual workloads and accelerating the time it takes for medical device and software-as-medical-device manufacturers to bring products to market. The company primarily serves regulatory affairs, quality, and reimbursement experts, as well as health technology companies across geographical markets, including the USA, EU, China, and emerging markets. Through their platform, Guideways.

ai addresses the need for faster regulatory compliance and supports clients in navigating the complexities of ever-evolving regulations. Guideways. ai generates revenue through a subscription-based model that allows clients to access their integrated AI platform tailored for regulatory and quality processes. Clients, including consulting firms and health technology manufacturers, engage with the platform by subscribing to various service tiers that provide access to specific functionalities, such as automated gap analysis and post-market surveillance.

This transaction structure facilitates direct engagement with B2B clients who benefit from expedited project completions and improved operational efficiency. The company's flagship offerings are designed to meet the needs of their client base in diverse markets while ensuring compliance with regulatory standards, although specific pricing and revenue figures for these services are not publicly disclosed The company plans to utilize this funding to launch and scale its artificial intelligence platform for regulatory approval, support a commercial rollout, and expand into European MDR and reimbursement frameworks.